GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conatus Pharmaceuticals Inc (NAS:CNAT) » Definitions » Purchase Of Investment

Conatus Pharmaceuticals (Conatus Pharmaceuticals) Purchase Of Investment : $-11.07 Mil (TTM As of Mar. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Conatus Pharmaceuticals Purchase Of Investment?

Conatus Pharmaceuticals's purchase of investment for the three months ended in Mar. 2020 was $0.00 Mil. It means Conatus Pharmaceuticals spent $0.00 Mil on purchasing investments. Conatus Pharmaceuticals's purchase of investment for the trailing twelve months (TTM) ended in Mar. 2020 was $-11.07 Mil.

Compared with last quarter ($0.00 Mil in Dec. 2019 ), Conatus Pharmaceuticals spent the same money on purchasing investments in Mar. 2020 ($0.00 Mil).

Conatus Pharmaceuticals Purchase Of Investment Historical Data

The historical data trend for Conatus Pharmaceuticals's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conatus Pharmaceuticals Purchase Of Investment Chart

Conatus Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Purchase Of Investment
Get a 7-Day Free Trial Premium Member Only -58.37 -40.91 -121.72 -39.64 -15.49

Conatus Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Purchase Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.42 -10.08 -0.99 - -

Conatus Pharmaceuticals Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Mar. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Conatus Pharmaceuticals Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Conatus Pharmaceuticals's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Conatus Pharmaceuticals (Conatus Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conatus Pharmaceuticals Inc (NAS:CNAT) » Definitions » Purchase Of Investment
Comparable Companies
HEPA PDSB TTPH RGLS ADIL NVUS UMRX NTEC BIXT INTI OCSE:NOVO B ASX:CSL VRTX REGN XKRX:207940 SGEN MRNA ALXN XKRX:068270 INCY
Traded in Other Exchanges
N/A
Address
16745 West Bernardo Drive, Suite 250, San Diego, CA, USA, 92127
Website
https://www.conatuspharma.com
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. Conatus has also been developing CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways.